Hepatitis A booster vaccination: is there a need? (Q35548831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

review article

1 reference

title

Hepatitis A booster vaccination: is there a need? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

author name string

P Van Damme

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

J Banatvala

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

O Fay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

S Iwarson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

B McMahon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

D Shouval

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

P Bonanni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

B Connor

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

G Cooksley

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

G Leroux-Roels

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

F Von Sonnenburg

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

International Consensus Group on Hepatitis A Virus Immunity

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

English

0 references

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

9389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

1065-1071

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Protecting travellers from hepatitis A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Seroprevalence of viral hepatitis A in the Czech Republic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Vaccination of travelers against hepatitis A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Hepatitis A and B in children and adolescents – what can we learn from Puglia (Italy) and Catalonia (Spain)?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Prospects for vaccination against hepatitis A and B in Catalonia (Spain)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Secular trends in hepatitis A virus infection among Alaska Natives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Hepatitis transmission among the Sioux Indians of South Dakota

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Inactivated virosome hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Are we giving too many doses of hepatitis A and B vaccines?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Serology and interferon production during the early phase of acute hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Immunologic approaches to assessing the response to inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Vaccination against hepatitis A in children aged 12 to 24 months [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

The case for routine childhood vaccination against hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Interruption of an outbreak of hepatitis A in two villages by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Long-term follow-up of hepatitis A vaccination in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Response to Hepatitis A Vaccine in Children after a Single Dose with a Booster Administration 6 Months Later

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Six years' follow-up after hepatitis A vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Combining hepatitis A and B vaccination in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

The first combined vaccine against hepatitis A and B: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914418-2

7 January 2021

10.1016/S0140-6736(03)14418-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14522539%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference